HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Anthrax vaccine antigen-adjuvant formulations completely protect New Zealand white rabbits against challenge with Bacillus anthracis Ames strain spores.

Abstract
In an effort to develop an improved anthrax vaccine that shows high potency, five different anthrax protective antigen (PA)-adjuvant vaccine formulations that were previously found to be efficacious in a nonhuman primate model were evaluated for their efficacy in a rabbit pulmonary challenge model using Bacillus anthracis Ames strain spores. The vaccine formulations include PA adsorbed to Alhydrogel, PA encapsulated in liposomes containing monophosphoryl lipid A, stable liposomal PA oil-in-water emulsion, PA displayed on bacteriophage T4 by the intramuscular route, and PA mixed with Escherichia coli heat-labile enterotoxin administered by the needle-free transcutaneous route. Three of the vaccine formulations administered by the intramuscular or the transcutaneous route as a three-dose regimen induced 100% protection in the rabbit model. One of the formulations, liposomal PA, also induced significantly higher lethal toxin neutralizing antibodies than PA-Alhydrogel. Even 5 months after the second immunization of a two-dose regimen, rabbits vaccinated with liposomal PA were 100% protected from lethal challenge with Ames strain spores. In summary, the needle-free skin delivery and liposomal formulation that were found to be effective in two different animal model systems appear to be promising candidates for next-generation anthrax vaccine development.
AuthorsKristina K Peachman, Qin Li, Gary R Matyas, Sathish B Shivachandra, Julie Lovchik, Rick C Lyons, Carl R Alving, Venigalla B Rao, Mangala Rao
JournalClinical and vaccine immunology : CVI (Clin Vaccine Immunol) Vol. 19 Issue 1 Pg. 11-6 (Jan 2012) ISSN: 1556-679X [Electronic] United States
PMID22089245 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, U.S. Gov't, Non-P.H.S.)
Chemical References
  • Adjuvants, Immunologic
  • Anthrax Vaccines
  • Antibodies, Bacterial
  • Antibodies, Neutralizing
  • Antigens, Bacterial
  • Antitoxins
  • Bacterial Toxins
  • Enterotoxins
  • Escherichia coli Proteins
  • Liposomes
  • heat-labile enterotoxin, E coli
Topics
  • Adjuvants, Immunologic (administration & dosage)
  • Administration, Cutaneous
  • Animals
  • Anthrax (prevention & control)
  • Anthrax Vaccines (administration & dosage, immunology)
  • Antibodies, Bacterial
  • Antibodies, Neutralizing (blood)
  • Antigens, Bacterial (immunology)
  • Antitoxins (blood)
  • Bacillus anthracis (immunology)
  • Bacterial Toxins (administration & dosage)
  • Bacteriophage T4
  • Disease Models, Animal
  • Enterotoxins (administration & dosage)
  • Escherichia coli Proteins (administration & dosage)
  • Female
  • Injections, Intramuscular
  • Liposomes (administration & dosage)
  • Nanoparticles (administration & dosage)
  • Rabbits
  • Survival Analysis
  • Time Factors

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: